EGF and cancer: More than 10 clinical trials have been completed with the therapeutic cancer vaccine CIMAvax-EGF, including phase II, III, and IV trials, demonstrating safety, long-term immunogenicity and a significant effect on survival, with several patients achieving long-term survival after vaccination [10].